Amgen Builds Biologics Facility in North Carolina

13.08.2021 - US biotech Amgen is planning to spend $550 million on building a new biologics manufacturing plant in Holly Springs, Wake County in North Carolina. Construction is scheduled to start in December with completion estimated for late 2024. The facility is anticipated to provide up to 355 full-time jobs in the region by 2029, including engineers, technicians, and quality, management and administrative roles.

Amgen is investing in a technologically-advanced drug substance plant in North Carolina to support the expected increase in demand for our medicines. Together with the previously announced advanced packaging plant in Ohio, we have committed to investing nearly $1 billion in new manufacturing capacity in the United States,” executive vice president of operations Esteban Santos.

The Holly Springs facility will be located near the Raleigh-Durham area’s Research Triangle Park, anchored by the major research universities of North Carolina State University, Duke University and University of North Carolina.

Amgen said the new plant will support both traditional stainless steel-fed batch manufacturing and next-generation single-use technologies, allowing flexibility for multiple pipeline products in one plant. This flexibility, which Amgen terms FleXBatch, means manufacturing is also more efficient and requires a smaller physical footprint than a traditional plant. The facility is also expected to have a 50% lower carbon footprint and half the water consumption of a traditional drug substance manufacturing plant.

The project will be partially facilitated by a grant approved by North Carolina’s Economic Investment Committee. Amgen could receive more than $11 million in reimbursements spread over 12 years. Economists at the Department of Commerce estimate that the project will grow the state’s economy by $2.5 billion.

In June, Amgen said it would invest $365 million at its Columbus site in Ohio to build a new greenfield plant to assemble and package vials and syringes to support growing demand for its medicines. Construction is expected to begin in the fall of 2021 with the site operational by 2024.

Author: Elaine Burridge, Freelance Journalist